Cardiff Oncology Stock Investor Sentiment

CRDF Stock  USD 2.66  0.05  1.92%   
Roughly 69% of Cardiff Oncology's investor base is looking to short. The analysis of the overall investor sentiment regarding Cardiff Oncology suggests that many traders are alarmed. The current market sentiment, together with Cardiff Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Cardiff Oncology stock news signals to limit their universe of possible portfolio assets.
  

Cardiff Oncology Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Cardiff Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at finance.yahoo.com         
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib i...
Yahoo News
over a year ago at zacks.com         
Has Cardiff Oncology Outpaced Other Medical Stocks This Year?
zacks News
over a year ago at finance.yahoo.com         
Has Cardiff Oncology Outpaced Other Medical Stocks This Year?
Yahoo News
over a year ago at www.macroaxis.com         
Acquisition by Tod Smeal of 167088 shares of Cardiff Oncology subject to Rule 16b-3
Macroaxis News
over a year ago at thelincolnianonline.com         
Short Interest in Cardiff Oncology, Inc. Decreases By 11.5
news
over a year ago at news.google.com         
Cardiff Oncology Formally Introduces Scientific Advisory Board - Cardiff Oncology Investor Relations
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Cardiff Oncology Full Year 2022 Earnings Beats Expectations
Yahoo News
over a year ago at zacks.com         
Cardiff Oncology Reports Q4 Loss, Tops Revenue Estimates
zacks News
over a year ago at investing.com         
Cardiff Oncology earnings beat by 0.02, revenue topped estimates
Investing News at Macroaxis
over a year ago at finance.yahoo.com         
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Yahoo News
over a year ago at news.google.com         
Regarding announcement of AUGA group, AB interim information for 12-month period ending in 31 Decemb...
Google News at Macroaxis
over a year ago at news.google.com         
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care ... - Cardiff Oncology Investor Rel...
Google News at Macroaxis
over a year ago at simplywall.st         
Heres Why Were Not Too Worried About Cardiff Oncologys Cash Burn Situation
Simply Wall St News at Macroaxis
over a year ago at thelincolnianonline.com         
Short Interest in Cardiff Oncology, Inc. Decreases By 9.4
news
over a year ago at news.google.com         
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar ... - Cardiff Oncology Investor Rel...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Cardiff Oncology that are available to investors today. That information is available publicly through Cardiff media outlets and privately through word of mouth or via Cardiff internal channels. However, regardless of the origin, that massive amount of Cardiff data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cardiff Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cardiff Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cardiff Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cardiff Oncology alpha.

Cardiff Oncology Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Jacob Gary S of 223 shares of Cardiff Oncology at 516.96 subject to Rule 16b-3
09/13/2024
2
Acquisition by Pace Gary W of 29700 shares of Cardiff Oncology at 2.33 subject to Rule 16b-3
10/01/2024
3
Cardiff Oncology Inc Q2 2024 Earnings Call Highlights Strategic Trials and Financial ...
10/09/2024
4
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
11/07/2024
5
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS ...
11/19/2024

Complementary Tools for Cardiff Stock analysis

When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Global Correlations
Find global opportunities by holding instruments from different markets